Stephanie Yacoubian, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fracture Fixation, Intramedullary | 3 | 2015 | 156 | 0.910 |
Why?
|
| Arthroplasty, Replacement, Knee | 4 | 2015 | 1458 | 0.770 |
Why?
|
| Femoral Neck Fractures | 2 | 2011 | 138 | 0.700 |
Why?
|
| Tibial Fractures | 2 | 2015 | 269 | 0.590 |
Why?
|
| Patellar Ligament | 1 | 2015 | 60 | 0.500 |
Why?
|
| Bone Nails | 2 | 2015 | 219 | 0.490 |
Why?
|
| Achilles Tendon | 1 | 2015 | 157 | 0.440 |
Why?
|
| Arthroplasty, Replacement, Hip | 2 | 2015 | 1462 | 0.410 |
Why?
|
| Postoperative Hemorrhage | 1 | 2015 | 413 | 0.400 |
Why?
|
| Tendon Injuries | 1 | 2015 | 313 | 0.400 |
Why?
|
| Blood Loss, Surgical | 1 | 2015 | 662 | 0.390 |
Why?
|
| Polyethylene | 1 | 2011 | 184 | 0.370 |
Why?
|
| Peroneal Neuropathies | 1 | 2010 | 20 | 0.370 |
Why?
|
| Peroneal Nerve | 1 | 2010 | 74 | 0.370 |
Why?
|
| Tibia | 2 | 2015 | 1077 | 0.350 |
Why?
|
| Tourniquets | 1 | 2010 | 110 | 0.340 |
Why?
|
| Sutures | 1 | 2011 | 299 | 0.340 |
Why?
|
| Accidents, Occupational | 1 | 2010 | 251 | 0.330 |
Why?
|
| Blood Transfusion | 1 | 2015 | 1301 | 0.330 |
Why?
|
| Fractures, Stress | 1 | 2010 | 187 | 0.320 |
Why?
|
| Knee Prosthesis | 1 | 2011 | 425 | 0.320 |
Why?
|
| Suture Techniques | 1 | 2011 | 798 | 0.280 |
Why?
|
| Prosthesis Failure | 1 | 2011 | 1206 | 0.280 |
Why?
|
| Lipoxins | 2 | 2008 | 412 | 0.270 |
Why?
|
| Inflammation Mediators | 3 | 2012 | 1889 | 0.260 |
Why?
|
| Workplace | 1 | 2010 | 836 | 0.240 |
Why?
|
| Osteoarthritis, Knee | 1 | 2011 | 1222 | 0.190 |
Why?
|
| Rheumatic Diseases | 1 | 2007 | 592 | 0.190 |
Why?
|
| Mediastinal Neoplasms | 1 | 2022 | 423 | 0.160 |
Why?
|
| Recovery of Function | 3 | 2015 | 2925 | 0.160 |
Why?
|
| Mesothelioma | 1 | 2023 | 818 | 0.150 |
Why?
|
| Airway Obstruction | 1 | 2022 | 664 | 0.140 |
Why?
|
| Bronchoscopy | 1 | 2022 | 862 | 0.140 |
Why?
|
| Docosahexaenoic Acids | 3 | 2012 | 875 | 0.130 |
Why?
|
| Fractures, Comminuted | 1 | 2015 | 52 | 0.130 |
Why?
|
| Blood Cell Count | 1 | 2015 | 403 | 0.120 |
Why?
|
| Anesthesia, General | 1 | 2022 | 1171 | 0.120 |
Why?
|
| Rupture | 1 | 2015 | 433 | 0.120 |
Why?
|
| Radiography | 3 | 2011 | 7023 | 0.110 |
Why?
|
| Inflammation | 3 | 2012 | 10638 | 0.100 |
Why?
|
| Reoperation | 2 | 2011 | 4201 | 0.100 |
Why?
|
| Femoral Fractures | 1 | 2015 | 376 | 0.100 |
Why?
|
| Acute Kidney Injury | 1 | 2023 | 1972 | 0.090 |
Why?
|
| Fires | 1 | 2010 | 173 | 0.080 |
Why?
|
| Equipment Failure | 1 | 2011 | 578 | 0.080 |
Why?
|
| Subcutaneous Fat | 1 | 2012 | 391 | 0.080 |
Why?
|
| Titanium | 1 | 2011 | 494 | 0.080 |
Why?
|
| Phagocytes | 1 | 2010 | 297 | 0.080 |
Why?
|
| Bone Screws | 1 | 2010 | 520 | 0.070 |
Why?
|
| Hip Fractures | 1 | 2015 | 955 | 0.070 |
Why?
|
| Prostaglandins | 1 | 2007 | 405 | 0.070 |
Why?
|
| Physical Therapy Modalities | 1 | 2010 | 550 | 0.070 |
Why?
|
| Leukotrienes | 1 | 2007 | 255 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2011 | 2618 | 0.070 |
Why?
|
| Femur | 1 | 2011 | 1297 | 0.060 |
Why?
|
| Range of Motion, Articular | 1 | 2011 | 1578 | 0.060 |
Why?
|
| Prosthesis Design | 1 | 2011 | 2110 | 0.060 |
Why?
|
| Aged | 6 | 2022 | 163280 | 0.060 |
Why?
|
| Fracture Fixation, Internal | 1 | 2010 | 917 | 0.060 |
Why?
|
| Hip Joint | 1 | 2010 | 1002 | 0.060 |
Why?
|
| Recurrence | 1 | 2015 | 8340 | 0.060 |
Why?
|
| Knee Joint | 1 | 2011 | 1680 | 0.050 |
Why?
|
| Activities of Daily Living | 1 | 2011 | 2418 | 0.050 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2010 | 1222 | 0.050 |
Why?
|
| Surgical Wound Infection | 1 | 2011 | 1540 | 0.050 |
Why?
|
| Female | 8 | 2022 | 380194 | 0.050 |
Why?
|
| Bradycardia | 1 | 2023 | 307 | 0.050 |
Why?
|
| Humans | 15 | 2023 | 744343 | 0.050 |
Why?
|
| Wound Healing | 1 | 2011 | 2785 | 0.050 |
Why?
|
| Magnesium | 1 | 2023 | 813 | 0.050 |
Why?
|
| Adult | 5 | 2022 | 214055 | 0.040 |
Why?
|
| Leukocytes | 1 | 2007 | 2043 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2010 | 2916 | 0.040 |
Why?
|
| Middle Aged | 5 | 2022 | 213383 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 57776 | 0.040 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2007 | 1344 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2007 | 1790 | 0.040 |
Why?
|
| Male | 6 | 2022 | 350118 | 0.040 |
Why?
|
| Cisplatin | 1 | 2023 | 1662 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2015 | 63114 | 0.040 |
Why?
|
| Observer Variation | 1 | 2002 | 2593 | 0.030 |
Why?
|
| Aspirin | 1 | 2007 | 3282 | 0.030 |
Why?
|
| Pain | 1 | 2010 | 4986 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2011 | 7181 | 0.030 |
Why?
|
| Mice, Obese | 1 | 2012 | 424 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2023 | 8324 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2011 | 15295 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2010 | 39050 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2010 | 1899 | 0.020 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2010 | 871 | 0.020 |
Why?
|
| Young Adult | 1 | 2010 | 56430 | 0.010 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2008 | 582 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2011 | 77449 | 0.010 |
Why?
|
| Phylogeny | 1 | 2010 | 2803 | 0.010 |
Why?
|
| Animals | 3 | 2012 | 168757 | 0.010 |
Why?
|
| Actins | 1 | 2010 | 2121 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 2008 | 1889 | 0.010 |
Why?
|
| Protein Binding | 1 | 2010 | 9386 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2022 | 53288 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2002 | 35421 | 0.010 |
Why?
|
| Neutrophils | 1 | 2008 | 3719 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 21827 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2010 | 19229 | 0.010 |
Why?
|
| Mice | 2 | 2012 | 81183 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 12072 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2008 | 18029 | 0.010 |
Why?
|